CompletedNCT02137629
Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Miran MoonClinical Research Manager, Celgene Korea
- Intervention
- Vidaza®(drug)
- Enrollment
- 511 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2016
Study locations (30)
- Hallym University Sacred Heart Hospital, Anyang, South Korea
- Soon Chun Hyang University Hospital Bucheon, Bucheon-si, South Korea
- Kosin University Gospel Hospital, Busan, South Korea
- Dong-a University Medical Center, Busan, South Korea
- Pusan National University Hospital, Busan, South Korea
- Inje University Busan Paik Hospital, Busan, South Korea
- Inje University Haeundae Paik Hospital, Busan, South Korea
- Dongnam Inst. of Radiological & Medical Science, Busan, South Korea
- Soon Chun Hyang University Hospital Cheonan, Cheonan, South Korea
- Chungbuk National University Hospital, Cheongju-si, South Korea
- Keimyung University Dongsan Hospital, Daegu, South Korea
- Kyungpook National University Hospital, Daegu, South Korea
- Daegu Fatima Hospita, Daegu, South Korea
- Yeungnam University Medical Center, Daegu, South Korea
- Daegu Catholic University Medical Center, Daegu, South Korea
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02137629 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute